EXELIXIS INC (EXEL)

US30161Q1040 - Common Stock

23.88  +0.02 (+0.08%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to EXEL. EXEL was compared to 592 industry peers in the Biotechnology industry. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. EXEL is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make EXEL suitable for value and quality investing!



7

1. Profitability

1.1 Basic Checks

In the past year EXEL was profitable.
In the past year EXEL had a positive cash flow from operations.
In the past 5 years EXEL has always been profitable.
In the past 5 years EXEL always reported a positive cash flow from operatings.

1.2 Ratios

EXEL's Return On Assets of 7.06% is amongst the best of the industry. EXEL outperforms 96.60% of its industry peers.
The Return On Equity of EXEL (9.18%) is better than 95.92% of its industry peers.
EXEL has a better Return On Invested Capital (5.31%) than 95.58% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is significantly below the industry average of 13.58%.
Industry RankSector Rank
ROA 7.06%
ROE 9.18%
ROIC 5.31%
ROA(3y)7.28%
ROA(5y)8.82%
ROE(3y)8.99%
ROE(5y)10.39%
ROIC(3y)7.03%
ROIC(5y)8.48%

1.3 Margins

The Profit Margin of EXEL (11.35%) is better than 96.26% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 9.34%, EXEL belongs to the best of the industry, outperforming 95.58% of the companies in the same industry.
EXEL's Operating Margin has declined in the last couple of years.
EXEL has a better Gross Margin (96.04%) than 96.43% of its industry peers.
In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
Industry RankSector Rank
OM 9.34%
PM (TTM) 11.35%
GM 96.04%
OM growth 3Y-5.74%
OM growth 5Y-28.9%
PM growth 3Y0.09%
PM growth 5Y-32.47%
GM growth 3Y-0.1%
GM growth 5Y-0.18%

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EXEL is destroying value.
Compared to 1 year ago, EXEL has less shares outstanding
Compared to 5 years ago, EXEL has more shares outstanding
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 7.51 indicates that EXEL is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.51, EXEL belongs to the top of the industry, outperforming 81.80% of the companies in the same industry.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.51
ROIC/WACC0.59
WACC9.02%

2.3 Liquidity

A Current Ratio of 3.34 indicates that EXEL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.34, EXEL is doing worse than 63.61% of the companies in the same industry.
A Quick Ratio of 3.30 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Quick ratio of 3.30. This is in the lower half of the industry: EXEL underperforms 63.27% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 3.3

5

3. Growth

3.1 Past

EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.28%, which is quite good.
Measured over the past years, EXEL shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.85% on average per year.
Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 13.60% in the last year.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 16.47% on average per year.
EPS 1Y (TTM)12.28%
EPS 3Y22.28%
EPS 5Y-14.85%
EPS growth Q2Q400%
Revenue 1Y (TTM)13.6%
Revenue growth 3Y22.83%
Revenue growth 5Y16.47%
Revenue growth Q2Q13.15%

3.2 Future

The Earnings Per Share is expected to grow by 30.94% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.49% on average over the next years.
EPS Next Y92.25%
EPS Next 2Y52.13%
EPS Next 3Y45.5%
EPS Next 5Y30.94%
Revenue Next Year3.96%
Revenue Next 2Y6.1%
Revenue Next 3Y8.17%
Revenue Next 5Y7.49%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 37.31 indicates a quite expensive valuation of EXEL.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.24% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.42. EXEL is valued slightly more expensive when compared to this.
EXEL is valuated rather expensively with a Price/Forward Earnings ratio of 19.41.
96.94% of the companies in the same industry are more expensive than EXEL, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.74, EXEL is valued at the same level.
Industry RankSector Rank
PE 37.31
Fwd PE 19.41

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaper than 94.90% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, EXEL is valued cheaply inside the industry as 96.43% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 24.72
EV/EBITDA 28.01

4.3 Compensation for Growth

EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EXEL has a very decent profitability rating, which may justify a higher PE ratio.
EXEL's earnings are expected to grow with 45.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y52.13%
EPS Next 3Y45.5%

0

5. Dividend

5.1 Amount

No dividends for EXEL!.
Industry RankSector Rank
Dividend Yield N/A

EXELIXIS INC

NASDAQ:EXEL (3/28/2024, 10:01:03 AM)

23.88

+0.02 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.24B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 37.31
Fwd PE 19.41
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.4
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.06%
ROE 9.18%
ROCE
ROIC
ROICexc
ROICexgc
OM 9.34%
PM (TTM) 11.35%
GM 96.04%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.34
Quick Ratio 3.3
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)12.28%
EPS 3Y22.28%
EPS 5Y
EPS growth Q2Q
EPS Next Y92.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.6%
Revenue growth 3Y22.83%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y